- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04310371
Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)
Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.
In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.
There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.
Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).
Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.
Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Clermont-Ferrand, Francja, 63000
- CHU de Clermont-Ferrand
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- age between 12 and 16 years old
- mature (menarche)
- suitable for physical activity
- able to give an informative consent
- affiliated at French insurance company
- consent from the legal representatives
- For obese adolescents: BMI greater than the 97th percentile of national curves.
- For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
Exclusion Criteria:
- Medical or surgical history judged by the investigator as incompatible with the study
- Drugs that may interfere with the study results
- Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
- Smoking
- Alcohol consumption
- Intense physical activity in competition
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Obese adolescents
BMI greater than the 97th percentile of national curves.
Participants will follow a 3-month lifestyle intervention
|
Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week. There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only. |
Brak interwencji: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
cardiac ectopic fat deposits
Ramy czasowe: Month 3
|
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
|
Month 3
|
cardiac ectopic fat deposits
Ramy czasowe: Day 0
|
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
|
Day 0
|
cardiac ectopic fat deposits
Ramy czasowe: Day 0
|
Quantification of cardiac ectopic fat deposits (volume using MRI)
|
Day 0
|
cardiac ectopic fat deposits
Ramy czasowe: Month 3
|
Quantification of cardiac ectopic fat deposits (volume using MRI)
|
Month 3
|
cardiac ectopic fat deposits
Ramy czasowe: Month 3
|
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
|
Month 3
|
cardiac ectopic fat deposits
Ramy czasowe: Day 0
|
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
|
Day 0
|
left myocardial regional function
Ramy czasowe: Month 3
|
left myocardial regional function (echocardiography)
|
Month 3
|
left myocardial regional function
Ramy czasowe: Month 3
|
left myocardial regional function (MRI)
|
Month 3
|
left myocardial regional function
Ramy czasowe: Day 0
|
left myocardial regional function (echocardiography)
|
Day 0
|
left myocardial regional function
Ramy czasowe: Day 0
|
left myocardial regional function (MRI)
|
Day 0
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
macrovascularisation
Ramy czasowe: Day 0
|
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
|
Day 0
|
macrovascularisation
Ramy czasowe: Month 3
|
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
|
Month 3
|
microvascularisation
Ramy czasowe: Month 3
|
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
|
Month 3
|
microvascularisation
Ramy czasowe: Day 0
|
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
|
Day 0
|
microvascularisation
Ramy czasowe: Day 0
|
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
|
Day 0
|
microvascularisation
Ramy czasowe: Month 3
|
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
|
Month 3
|
microvascularisation
Ramy czasowe: Month 3
|
measure of microvascular perfusion using Iontophoresis procedure
|
Month 3
|
microvascularisation
Ramy czasowe: Day 0
|
measure of microvascular perfusion using Iontophoresis procedure
|
Day 0
|
microvascularisation
Ramy czasowe: Day 0
|
measure of microvascular perfusion using flowmotion
|
Day 0
|
microvascularisation
Ramy czasowe: Month 3
|
measure of microvascular perfusion using flowmotion
|
Month 3
|
heart rate variability
Ramy czasowe: Month 3
|
measure of heart rate variability using a holter
|
Month 3
|
heart rate variability
Ramy czasowe: Day 0
|
measure of heart rate variability using a holter
|
Day 0
|
skin conductance
Ramy czasowe: Day 0
|
measure of skin conductance using Wristband electrodes - Empatica E4
|
Day 0
|
skin conductance
Ramy czasowe: Month 3
|
measure of skin conductance using Wristband electrodes - Empatica E4
|
Month 3
|
Liver steatosis
Ramy czasowe: Month 3
|
measure of liver steatosis by MRI
|
Month 3
|
Liver steatosis
Ramy czasowe: Day 0
|
measure of liver steatosis by MRI
|
Day 0
|
Liver steatosis
Ramy czasowe: Day 0
|
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
|
Day 0
|
Liver steatosis
Ramy czasowe: Month 3
|
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
|
Month 3
|
Liver steatosis
Ramy czasowe: month 3
|
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
|
month 3
|
Liver steatosis
Ramy czasowe: Day 0
|
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
|
Day 0
|
Liver fibrosis
Ramy czasowe: Day 0
|
measure of liver fibrosis by fibroscanner (liver stiffness)
|
Day 0
|
Liver fibrosis
Ramy czasowe: Month 3
|
measure of liver fibrosis by fibroscanner (liver stiffness)
|
Month 3
|
Liver fibrosis
Ramy czasowe: Month 3
|
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
|
Month 3
|
Liver fibrosis
Ramy czasowe: Day 0
|
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
|
Day 0
|
blood pressure
Ramy czasowe: Day0
|
measure of blood pressure using sphygmomanometer
|
Day0
|
blood pressure
Ramy czasowe: month 3
|
measure of blood pressure using sphygmomanometer
|
month 3
|
Fitness
Ramy czasowe: Month 3
|
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
|
Month 3
|
Fitness
Ramy czasowe: Day 0
|
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
|
Day 0
|
muscle mass
Ramy czasowe: Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
fat mass
Ramy czasowe: Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
bone structure
Ramy czasowe: Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
muscle mass
Ramy czasowe: Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
fat mass
Ramy czasowe: Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
bone structure
Ramy czasowe: Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
muscle mass
Ramy czasowe: Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
fat mass
Ramy czasowe: Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
bone structure
Ramy czasowe: Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
muscle mass
Ramy czasowe: Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
fat mass
Ramy czasowe: Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
bone structure
Ramy czasowe: Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
muscle mass
Ramy czasowe: Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
fat mass
Ramy czasowe: Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
bone structure
Ramy czasowe: Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
muscle mass
Ramy czasowe: Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
fat mass
Ramy czasowe: Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
bone structure
Ramy czasowe: Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
muscle mass
Ramy czasowe: Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
fat mass
Ramy czasowe: Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
bone structure
Ramy czasowe: Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
muscle mass
Ramy czasowe: Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
fat mass
Ramy czasowe: Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
bone structure
Ramy czasowe: Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
depression
Ramy czasowe: Day 0
|
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
|
Day 0
|
depression
Ramy czasowe: Month 3
|
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
|
Month 3
|
anxiety
Ramy czasowe: Day 0
|
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
|
Day 0
|
anxiety
Ramy czasowe: Month 3
|
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
|
Month 3
|
General health
Ramy czasowe: Day 0
|
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
|
Day 0
|
General health
Ramy czasowe: Month 3
|
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
|
Month 3
|
Stress
Ramy czasowe: day 0
|
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
day 0
|
Stress
Ramy czasowe: Month 3
|
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Month 3
|
Fatigue
Ramy czasowe: Day 0
|
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Day 0
|
Fatigue
Ramy czasowe: Month 3
|
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Month 3
|
Sleep
Ramy czasowe: day 0
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
day 0
|
Sleep
Ramy czasowe: Month 3
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
Month 3
|
Burnout
Ramy czasowe: day 0
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
day 0
|
Burnout
Ramy czasowe: Month 3
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
Month 3
|
Mindfulness
Ramy czasowe: Day 0
|
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
|
Day 0
|
Mindfulness
Ramy czasowe: Month 3
|
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
|
Month 3
|
Coping
Ramy czasowe: Day 0
|
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
|
Day 0
|
Coping
Ramy czasowe: Month 3
|
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
|
Month 3
|
Emotions
Ramy czasowe: Day 0
|
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
|
Day 0
|
Emotions
Ramy czasowe: Month 3
|
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
|
Month 3
|
Perception of work
Ramy czasowe: Day 0
|
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree).
It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
|
Day 0
|
Perception of work
Ramy czasowe: Month 3
|
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree).
It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
|
Month 3
|
Self-efficacy
Ramy czasowe: Day 0
|
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
|
Day 0
|
Self-efficacy
Ramy czasowe: Month 3
|
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
|
Month 3
|
Alexithymia
Ramy czasowe: Day 0
|
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
|
Day 0
|
Alexithymia
Ramy czasowe: Month 3
|
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
|
Month 3
|
Illness perception
Ramy czasowe: Day 0
|
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
|
Day 0
|
Illness perception
Ramy czasowe: Month 3
|
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
|
Month 3
|
Metacognition
Ramy czasowe: Day 0
|
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
|
Day 0
|
Metacognition
Ramy czasowe: Month 3
|
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
|
Month 3
|
Time perception
Ramy czasowe: Day 0
|
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale.
It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
|
Day 0
|
Time perception
Ramy czasowe: Month 3
|
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale.
It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
|
Month 3
|
Physical activity
Ramy czasowe: Day 0
|
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
|
Day 0
|
Physical activity
Ramy czasowe: Month 3
|
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
|
Month 3
|
Life style
Ramy czasowe: Day 0
|
life style is assessed with a questionnaire on coffee consumption, food intake, etc
|
Day 0
|
Life style
Ramy czasowe: Month 3
|
life style is assessed with a questionnaire on coffee consumption, food intake, etc
|
Month 3
|
cholesterol
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate alloplastic load
|
Day 0
|
triglycerides
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate alloplastic load
|
Day 0
|
cholesterol
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate alloplastic load
|
Month 3
|
triglycerides
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate alloplastic load
|
Month 3
|
Cortisol
Ramy czasowe: Day 0
|
hormone measure by blood analyses to evaluate alloplastic load
|
Day 0
|
Cortisol
Ramy czasowe: Month 3
|
hormone measure by blood analyses to evaluate alloplastic load
|
Month 3
|
DHEAS
Ramy czasowe: day 0
|
hormone measure by blood analyses to evaluate alloplastic load
|
day 0
|
DHEAS
Ramy czasowe: Month 3
|
hormone measure by blood analyses to evaluate alloplastic load
|
Month 3
|
BDNF
Ramy czasowe: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
BDNF
Ramy czasowe: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
CRP
Ramy czasowe: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
pro-inflammatory cytokines
Ramy czasowe: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
TNF alpha
Ramy czasowe: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
CRP
Ramy czasowe: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
pro-inflammatory cytokines
Ramy czasowe: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
TNF alpha
Ramy czasowe: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
NPY
Ramy czasowe: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
NPY
Ramy czasowe: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
Leptin
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
Leptin
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
Ghrelin
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
Ghrelin
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
NPY
Ramy czasowe: day 0
|
measure by blood analyses to evaluate appetite regulation
|
day 0
|
NPY
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
adiponectine
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
adiponectine
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
CCK
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
Month 3
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
Insulin
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
Insulin
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
HbA1c
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
HbA1c
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
glucose
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
glucose
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
Albumin
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate protid metabolism
|
Day 0
|
Albumin
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate protid metabolism
|
Month 3
|
transthyretin
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate protid metabolism
|
Day 0
|
transthyretin
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate protid metabolism
|
Month 3
|
Homeostasis
Ramy czasowe: Day 0
|
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
|
Day 0
|
Homeostasis
Ramy czasowe: Month 3
|
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
|
Month 3
|
Osteoresorption
Ramy czasowe: Day 0
|
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
|
Day 0
|
Osteoresorption
Ramy czasowe: Month 3
|
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
|
Month 3
|
Osteoformation
Ramy czasowe: Day 0
|
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
|
Day 0
|
Osteoformation
Ramy czasowe: Month 3
|
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
|
Month 3
|
VEGF
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate cardiovascular function
|
Day 0
|
VEGF
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate cardiovascular function
|
Month 3
|
PAI1
Ramy czasowe: Day 0
|
measure by blood analyses to evaluate cardiovascular function
|
Day 0
|
PAI1
Ramy czasowe: Month 3
|
measure by blood analyses to evaluate cardiovascular function
|
Month 3
|
weight
Ramy czasowe: Day 0
|
measure of weight in kilograms
|
Day 0
|
weight
Ramy czasowe: Month 3
|
measure of weight in kilograms
|
Month 3
|
waist circumference
Ramy czasowe: Day 0
|
measure of waist circumference in centimetres
|
Day 0
|
waist circumference
Ramy czasowe: Month 3
|
measure of waist circumference in centimetres
|
Month 3
|
Współpracownicy i badacze
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Oczekiwany)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- RBHP 2019 DUTHEIL
- 2019-A01804-53 (Inny identyfikator: ANSM)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .